Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective Randomized Controlled Clinical Trial

NCT04137653 is registered in ClinicalTrials.gov with Shengjing Hospital as lead sponsor.

NCT NCT04137653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04137653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective Randomized Controlled Clinical Trial
Lead sponsor
Shengjing Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
July 19, 2021
Completion date
November 30, 2026
Enrollment
1,498 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer